北京2025/26季流感疫苗对A(H3N2)与B/Victoria的季末保护效果
研究基于北京流感哨点监测系统2025年第40周至2026年第21周的门诊流感样病例,采用检测阴性设计评估季末流感疫苗保护效果。共检测20749例,4875例(23.5%)流感阳性,以A(H3N2)与B/Victoria为主。调整后对任何流感保护效果为26.4%(95%CI:17.8至34.1)。
要点
- 对任何流感调整后保护效果26.4%,对B/Victoria为34.7%,高于A(H3N2)的22.2%。
- 18–59岁成人对任何流感的保护效果最高,为53.0%(95%CI:37.0至64.9)。
- 连续两季接种背景下的保护效果在A(H3N2)与B/Victoria间呈现不同模式。
核心结论
- 2025/26季流感疫苗接种使门诊实验室确诊流感减少约四分之一,18–59岁成人保护效果更高。
- 两季接种史的保护效果模式在A(H3N2)与B/Victoria间不同,支持流感疫苗接种的公共卫生价值与持续病毒学监测。
研究设计与样本
- 采用检测阴性设计,通过北京流感哨点病毒学监测系统纳入2025年第40周至2026年第21周的门诊流感样病例。
- 病例为流感检测阳性者,对照为检测阴性者,共检测20749例流感样病例。
- 使用非条件多因素logistic回归估计保护效果,调整年龄(自然三次样条)、性别、合并症、居住地区和日历周(自然三次样条)。
主要发现
- 20749例检测者中4875例(23.5%)流感阳性,以A(H3N2)与B/Victoria为主。
- 调整后保护效果:任何流感26.4%(95%CI:17.8至34.1),A(H3N2) 22.2%(95%CI:11.3至31.7),B/Victoria 34.7%(95%CI:19.6至47.0)。
- 18–59岁成人对任何流感的保护效果最高,为53.0%(95%CI:37.0至64.9)。
- B/Victoria方面,仅2025/26季接种者38.7%(95%CI:15.6至55.5)与两季均接种者35.1%(95%CI:16.5至49.6)相近,高于仅2024/25季接种者17.0%(95%CI:-16.1至40.7)。
- A(H3N2)方面,仅2025/26季接种者27.9%(95%CI:11.5至41.2)高于两季均接种者17.9%(95%CI:4.0至29.7)与仅2024/25季接种者-6.1%(95%CI:-28.7至12.5)。
临床怎么用
- 提示流感疫苗接种对门诊实验室确诊流感具有中等保护作用,应继续推动季节性流感疫苗接种。
- 应结合年龄与既往接种史解读保护效果,并持续开展病毒学监测以支持防控政策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to estimate the end-of-season influenza vaccine effectiveness (VE) against A(H3N2) and B/Victoria in the 2025/26 season in Beijing, China. METHODS: We used a test-negative design to assess influenza VE among outpatients with influenza-like illness (ILI) enrolled through the Beijing influenza sentinel virological surveillance system from September 2025 (week 40/2025) to May 2026 (week 21/2026). Cases were ILI patients who tested positive for influenza; controls were those who tested negative. The VE was estimated using non-conditional multiple logistic regression models, adjusting for age (modelled as a natural cubic spline), sex, presence of comorbidities, area of residence, and calendar week (modelled as a natural cubic spline). RESULTS: Among 20,749 ILI patients tested, 4875 (23.5%) were positive for influenza, with A(H3N2) and B/Victoria being the predominant strains. Adjusted VE was 26.4% (95% CI: 17.8 to 34.1) against any influenza, 22.2% (95% CI: 11.3 to 31.7) against A(H3N2), and 34.7% (95% CI: 19.6 to 47.0) against B/Victoria, with the highest VE observed in adults aged 18-59 years (53.0%, 95%CI: 37.0 to 64.9) against any influenza. The adjusted VE was similar for those vaccinated in 2025/26 only (38.7%, 95%CI: 15.6 to 55.5) or both 2024/25 and 2025/26 seasons (35.1%, 95%CI: 16.5 to 49.6), but higher than those vaccinated in 2024/25 only (17.0%, 95%CI: -16.1 to 40.7) among B/Victoria. For A(H3N2), the VE point estimate was higher among those vaccinated in the 2025/26 season only (27.9%, 95%CI: 11.5 to 41.2) than among those vaccinated in both seasons (17.9%, 95%CI: 4.0 to 29.7) and 2024/25 only (-6.1%, 95%CI: -28.7 to 12.5). CONCLUSION: Our findings indicate that seasonal vaccination reduced laboratory-confirmed influenza among outpatients by approximately a quarter, with higher VE in adults aged 18-59 years. VE estimates according to vaccination status over two consecutive seasons showed different patterns for A(H3N2) and B/Victoria. These real-world findings support the ongoing public health value of influenza vaccination and highlight the importance of continuous virological surveillance, prevention, and control policy.
引用
- Zhang, Shen, Shi, et al. End-of-season influenza vaccine effectiveness against a(H3N2) and B/Victoria in Beijing, China, 2025/26 season. Vaccine. 2026. PMID: 42950746. doi:10.1016/j.vaccine.2026.129273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。